<DOC>
	<DOC>NCT01572675</DOC>
	<brief_summary>This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).</brief_summary>
	<brief_title>A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Treatmentnaive, discontinued the previous treatment course of etoricoxib or celecoxib at least 3 months previously or currently receiving continuous treatment with oral etoricoxib or celecoxib Consent to take part in the study Included in his/her physician's client base for at least 1 year Unable to receive followup over a year Included in an interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pharmacoepidemiological</keyword>
	<keyword>Longitudinal</keyword>
	<keyword>Observational</keyword>
</DOC>